Implications of cytochrome P450 interactions when prescribing medication for hypertension

David A. Flockhart, Jose E. Tanus-Santos

Research output: Contribution to journalArticle

89 Citations (Scopus)

Abstract

Many of the estimated 50 million Americans with high blood pressure receive medications for hypertension and for other conditions, placing them at risk for adverse drug interactions. The risk for hypertension and for adverse drug reactions is highest in the elderly, who have the greatest need for pharmacologic therapy. The most important class of drug interactions involves the cytochrome P450 microsomal enzyme system, which handles a variety of xenobiotic substances. A potential for interactions with these enzymes exists with calcium channel blockers, β-adrenergic blocking agents, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers but not with diuretic antihypertensives, which are renally eliminated and more vulnerable to drug interactions that occur in the kidney. This article reviews the cytochrome P450 enzyme system, identifies drugs and foods that have been implicated in metabolic interactions with antihypertensive agents, and suggests measures for reducing the risk of adverse events when drugs are coadministered.

Original languageEnglish
Pages (from-to)405-412
Number of pages8
JournalArchives of Internal Medicine
Volume162
Issue number4
StatePublished - Feb 25 2002

Fingerprint

Cytochrome P-450 Enzyme System
Drug Interactions
Hypertension
Drug-Related Side Effects and Adverse Reactions
Antihypertensive Agents
Adrenergic Antagonists
Angiotensin Receptor Antagonists
Calcium Channel Blockers
Xenobiotics
Angiotensin-Converting Enzyme Inhibitors
Diuretics
Kidney
Food
Enzymes
Pharmaceutical Preparations
Therapeutics

ASJC Scopus subject areas

  • Internal Medicine

Cite this

Implications of cytochrome P450 interactions when prescribing medication for hypertension. / Flockhart, David A.; Tanus-Santos, Jose E.

In: Archives of Internal Medicine, Vol. 162, No. 4, 25.02.2002, p. 405-412.

Research output: Contribution to journalArticle

Flockhart, David A. ; Tanus-Santos, Jose E. / Implications of cytochrome P450 interactions when prescribing medication for hypertension. In: Archives of Internal Medicine. 2002 ; Vol. 162, No. 4. pp. 405-412.
@article{8be70399f51342cfbec6088633d2c61b,
title = "Implications of cytochrome P450 interactions when prescribing medication for hypertension",
abstract = "Many of the estimated 50 million Americans with high blood pressure receive medications for hypertension and for other conditions, placing them at risk for adverse drug interactions. The risk for hypertension and for adverse drug reactions is highest in the elderly, who have the greatest need for pharmacologic therapy. The most important class of drug interactions involves the cytochrome P450 microsomal enzyme system, which handles a variety of xenobiotic substances. A potential for interactions with these enzymes exists with calcium channel blockers, β-adrenergic blocking agents, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers but not with diuretic antihypertensives, which are renally eliminated and more vulnerable to drug interactions that occur in the kidney. This article reviews the cytochrome P450 enzyme system, identifies drugs and foods that have been implicated in metabolic interactions with antihypertensive agents, and suggests measures for reducing the risk of adverse events when drugs are coadministered.",
author = "Flockhart, {David A.} and Tanus-Santos, {Jose E.}",
year = "2002",
month = "2",
day = "25",
language = "English",
volume = "162",
pages = "405--412",
journal = "JAMA Internal Medicine",
issn = "2168-6106",
publisher = "American Medical Association",
number = "4",

}

TY - JOUR

T1 - Implications of cytochrome P450 interactions when prescribing medication for hypertension

AU - Flockhart, David A.

AU - Tanus-Santos, Jose E.

PY - 2002/2/25

Y1 - 2002/2/25

N2 - Many of the estimated 50 million Americans with high blood pressure receive medications for hypertension and for other conditions, placing them at risk for adverse drug interactions. The risk for hypertension and for adverse drug reactions is highest in the elderly, who have the greatest need for pharmacologic therapy. The most important class of drug interactions involves the cytochrome P450 microsomal enzyme system, which handles a variety of xenobiotic substances. A potential for interactions with these enzymes exists with calcium channel blockers, β-adrenergic blocking agents, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers but not with diuretic antihypertensives, which are renally eliminated and more vulnerable to drug interactions that occur in the kidney. This article reviews the cytochrome P450 enzyme system, identifies drugs and foods that have been implicated in metabolic interactions with antihypertensive agents, and suggests measures for reducing the risk of adverse events when drugs are coadministered.

AB - Many of the estimated 50 million Americans with high blood pressure receive medications for hypertension and for other conditions, placing them at risk for adverse drug interactions. The risk for hypertension and for adverse drug reactions is highest in the elderly, who have the greatest need for pharmacologic therapy. The most important class of drug interactions involves the cytochrome P450 microsomal enzyme system, which handles a variety of xenobiotic substances. A potential for interactions with these enzymes exists with calcium channel blockers, β-adrenergic blocking agents, angiotensin-converting enzyme inhibitors, and angiotensin receptor blockers but not with diuretic antihypertensives, which are renally eliminated and more vulnerable to drug interactions that occur in the kidney. This article reviews the cytochrome P450 enzyme system, identifies drugs and foods that have been implicated in metabolic interactions with antihypertensive agents, and suggests measures for reducing the risk of adverse events when drugs are coadministered.

UR - http://www.scopus.com/inward/record.url?scp=0037169960&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0037169960&partnerID=8YFLogxK

M3 - Article

C2 - 11863472

AN - SCOPUS:0037169960

VL - 162

SP - 405

EP - 412

JO - JAMA Internal Medicine

JF - JAMA Internal Medicine

SN - 2168-6106

IS - 4

ER -